MA Senate proposes outright gift ban

The leader of the Massachusetts State Senate has proposed legislation banning all gifts to doctors from pharmaceutical companies. If enacted, the move would make the state the first in the country to ban gifts outright.

“There's going to be a climate change, and there has to be a climate change; otherwise our healthcare reform will implode, just under the costs,” said Therese Murrary, Massachusetts State Senate president, in published reports.

Murray's measure is part of a set of healthcare reforms filed in a bill that also includes requiring all doctors statewide to adopt electronic medical records by 2015, allowing patients to choose nurse practitioners as primary care providers, and forcing public reviews of any insurance company efforts to boost annual premiums by more than 7%.

The ban forbids the industry from giving doctors—their families or employees—gifts from drug companies. Gifts include payments, entertainment, meals, travel, honorariums, subscriptions, even a pen with a drug company logo.

The legislation would continue to permit distribution of drug samples to doctors for the exclusive use of their patients. Anyone who violates the ban could be fined $5,000, face two years imprisonment, or both, under the proposal.

Currently Minnesota and Vermont are the only states with mandatory physician gift reporting laws.

In Minnesota, legislators enacted a ban on gifts in excess of $50 from pharmaceutical companies. In Vermont, legislators have passed laws requiring pharmaceutical company representatives to disclose the dollar value of gifts over $25 to doctors.

Julie Corcoran, deputy vice president of PhRMA, told The Boston Globe that the industry's sales people are “highly educated and trained by their companies.” The group opposes any ban, saying the pharmaceutical industry is already heavily regulated by the FDA.

“I'm not aware of any kind of evidence or studies that link promotional or marketing materials with the cost of healthcare,” she said.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.